MSLE — Satellos Bioscience Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1421642 · Ontario, Canada
Last close
$6.20
Market Cap
$131.54M
52W High
$13.40
52W Low
$5.44
ADV30
51,718
Next earnings
2026-11-12

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -11,677,000 -11,168,000 57,985,000 6,175,000 8,362,000
Jun 2026 0 — -12,165,000 -11,718,000 65,769,000 7,393,000 5,861,000
Mar 2026 0 — -10,043,000 -9,768,000 75,226,000 18,697,000 4,563,000
Dec 2025 0 — -7,647,000 -7,303,000 31,889,000 9,804,000 4,105,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-29,000,000
Investing CF
$-54,566,000
Financing CF
$52,785,000
CapEx
$-7,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.84
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-103,456,000
Inventory
—
Receivables
$783,000
ST Investments
$54,446,000
EBIT TTM
$-35,821,000
Pretax Income TTM
$-34,456,000
Interest Exp TTM
—
Analysts
6

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -26,459,000 -24,873,000 31,889,000 4,105,000 27,784,000 -23,596,000
Dec 2024 0 -20,398,000 -20,634,000 50,747,000 3,583,000 47,164,000 -18,252,000
Dec 2023 0 -11,656,113 -11,977,235 33,490,000 2,734,000 30,756,000 -8,732,851
Dec 2022 0 -6,209,844 -8,342,175 4,567,492 2,085,175 2,482,317 -4,260,978
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.73

Peers — same industry

TickerNameMarket CapLastDaily %
MGNX MACROGENICS INC $131.01M $2.05 —
MENS Jyong Biotech Ltd. $133.62M $1.80 —
NTHI NEONC TECHNOLOGIES HOLDINGS, INC. $124.92M $4.33 —
SION Sionna Therapeutics, Inc. $138.87M $3.07 —
ALXO ALX ONCOLOGY HOLDINGS INC $138.97M $1.00 —

News headlines (Yahoo Finance, 1h cache)

Satellos Bioscience's Phase 2 Data Readout Could Drive Significant Upside, Oppenheimer Says
2026-11-13 16:48 · Yahoo
Satellos Bioscience: Q3 Earnings Snapshot
2026-11-12 12:13 · Yahoo
Satellos Reports Third Quarter 2026 Financial Results and Highlights Company Progress
2026-11-12 12:00 · Yahoo
Satellos Bioscience Sets Duchenne Trial Endpoint After FDA Talks, Eyes 2027 Results
2026-11-07 02:14 · Yahoo
Satellos Changes Primary Efficacy Endpoint in BASECAMP Phase 2 Pediatric Trial to MRI-Measured Fat Fraction Following FDA Feedback
2026-11-06 12:00 · Yahoo
Satellos to Host Investor Call to Provide an Update on Clinical and Regulatory Strategy for the BASECAMP Phase 2 Pediatric Study
2026-11-05 21:32 · Yahoo
Satellos Establishes Scientific Advisory Board to Explore the Biology of Regeneration in Aging and Neuroscience
2026-10-27 11:00 · Yahoo
Satellos to Participate in Upcoming Investor Conferences
2026-10-21 11:00 · Yahoo
Satellos Bioscience Completes Enrollment in Phase 2 Basecamp Trial
2026-09-30 18:00 · Yahoo
Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy
2026-09-30 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.